

Role of EPS8 in prostate cancer treatments




Figure S1. Triplicates of the western blot analysis for the expression of EPS8 protein in the LNCaP Enz-R and LNCaP cell lines.

Role of EPS8 in prostate cancer treatments




Figure S2. Triplicates of the western blot analysis for the EMT markers expression in the LNCaP cell lines transfected with pCMV-EPS8 and pCMV-GFP.

Role of EPS8 in prostate cancer treatments




Figure S3. Triplicates of the western blot analysis for the EMT markers expression in the LNCap Enz-R cell lines transfected with pCMV-EPS8 and pCMV-GFP.

Role of EPS8 in prostate cancer treatments




Figure S4. Triplicates of the western blot analysis for the EMT markers expression in the LNCap cell lines transfected with shRNA-EPS8 and shRNA-control.

Role of EPS8 in prostate cancer treatments




Figure S5. Triplicates of the western blot analysis for the EMT markers expression in the LNCap Enz-R cell lines transfected with shRNA-EPS8 and shRNA-control.


Role of EPS8 in prostate cancer treatments

A


LNCap cell
E-cadherin 135KDa

pCMV-GFP

Repeat 1






Repeat 2



Repeat 3




pCMV-Eps8




LNCap cell
 α -SMA 42KDa

pCMV-GFP


Repeat 1






Repeat 2



Repeat 3




pCMV-Eps8




Role of EPS8 in prostate cancer treatments

B

LNcap cell
Snail 29KDa



LNcap cell
Slug 30KDa



Role of EPS8 in prostate cancer treatments







Figure S6. A. Triplicates of the western blot analysis for the EMT markers (E-cadherin and α -SMA) expression in the LNCaP cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors. B. Triplicates of the western blot analysis for the EMT markers (Snail and Slug) expression in the LNCaP cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors. C. Triplicates of the western blot analysis for the β -actin expression in the LNCaP cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors.

Role of EPS8 in prostate cancer treatments

A



Role of EPS8 in prostate cancer treatments



Role of EPS8 in prostate cancer treatments




Figure S7. A. Triplicates of the western blot analysis for the EMT markers (E-cadherin and α -SMA) expression in the LNCaP Enz-R cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors. B. Triplicates of the western blot analysis for the EMT markers (Snail and Slug) expression in the LNCaP Enz-R cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors. C. Triplicates of the western blot analysis for the β -actin expression in the LNCaP Enz-R cell lines after administration of Ras/p53/JAK/PI3K signaling inhibitors.

Role of EPS8 in prostate cancer treatments

Table S1. Tumor weights of each xenograft

	Control	pcDNA-control	pcDNA-EPS8	shRNA-control	shRNA-EPS8
Tumor Weights	52.40	56.00	86.80	64.00	27.60
	46.60	48.70	80.10	56.00	31.00
	50.00	56.70	80.90	35.00	33.40
	35.80	41.30	78.70	36.00	10.00
	45.00	46.60	85.00	45.00	21.80
Median	46.60	48.70	80.90	45.00	27.60
P-value	-	0.008*		0.008*	

Weights of each xenograft are shown. The median tumor weight was greater in the pcDNA-EPS8 and shRNA-control groups compared with the pcDNA-control and shRNA-EPS8 groups. Mann-Whitney U Test, *P < 0.05.